1. Home
  2. CRBU vs UIS Comparison

CRBU vs UIS Comparison

Compare CRBU & UIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caribou Biosciences Inc.

CRBU

Caribou Biosciences Inc.

HOLD

Current Price

$2.32

Market Cap

179.7M

Sector

Health Care

ML Signal

HOLD

Logo Unisys Corporation New

UIS

Unisys Corporation New

HOLD

Current Price

$2.72

Market Cap

164.7M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRBU
UIS
Founded
2011
1942
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
179.7M
164.7M
IPO Year
2021
1994

Fundamental Metrics

Financial Performance
Metric
CRBU
UIS
Price
$2.32
$2.72
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$10.75
$5.67
AVG Volume (30 Days)
1.2M
622.5K
Earning Date
05-07-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
3.64
N/A
EPS
N/A
N/A
Revenue
N/A
$1,950,100,000.00
Revenue This Year
$1.63
N/A
Revenue Next Year
$10.93
$2.60
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.73
$1.97
52 Week High
$3.53
$5.33

Technical Indicators

Market Signals
Indicator
CRBU
UIS
Relative Strength Index (RSI) 67.38 75.67
Support Level $1.70 $2.61
Resistance Level $2.66 $2.89
Average True Range (ATR) 0.11 0.11
MACD 0.03 0.08
Stochastic Oscillator 94.85 95.57

Price Performance

Historical Comparison
CRBU
UIS

About CRBU Caribou Biosciences Inc.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

About UIS Unisys Corporation New

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. maximum of revenue is from CA&I segment.

Share on Social Networks: